The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500 - 1/1000. Detects a band of approximately 34 kDa (predicted molecular weight: 35 kDa).
1/50 - 1/100.
FunctionRegulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily. Contains 1 cyclin N-terminal domain.
Cellular localizationNucleus. Cytoplasm. Membrane. Cyclin D-CDK4 complexes accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members.
All lanes : Anti-Cyclin D3 antibody (ab63535) at 1/500 dilution
Lane 1 : Extracts from COS7 cells (5-30ug), treated
with Forskolin (40nM, 30mins), without immunising peptide. Lane 2 : Extracts from COS7 cells (5-30ug), treated
with Forskolin (40nM, 30mins), with immunising peptide (5-10ug).
Ab63535 (1/50-1/100) staining human Cyclin D3 in human lung carcinoma tissue by immunohistochemistry using formalin fixed, paraffin embedded tissue.
The left hand panel is without immunising peptide, whereas the right hand panel is in the presence of immunising peptide.
References for Anti-Cyclin D3 antibody (ab63535)
This product has been referenced in:
Zhang X et al. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer. J Hematol Oncol10:29 (2017).
Read more (PubMed: 28114995) »